---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-197017"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:07:34.834968+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arcellx Q2 net loss $27.2M; earns $68M milestone from Kite; IND cleared for myasthenia gravis

## Summary
- Earned $68M milestone from Kite for iMMagine-1 enrollment in multiple myeloma.
- Cash, equivalents, and marketable securities $646.8M as of June 30, 2024; funds operations into 2027.
- Collaboration revenue $27.4M (up from $14.3M YoY); net loss $27.2M vs $23.9M YoY.
- FDA cleared anito-cel IND for myasthenia gravis, a chronic autoimmune disease; wholly owned by Arcellx.
- Kite initiated global Phase 3 iMMagine-3; abstract submitted for ASH Annual Meeting by year-end.

## SEC filing metadata
- accession: 0001193125-24-197017
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312524197017/0001193125-24-197017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312524197017/d874563d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-197017
- JSON: https://secwatch.observer/filing/0001193125-24-197017.json
- Plain text: https://secwatch.observer/filing/0001193125-24-197017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.